Trial · NCT05104723
Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
NCT05104723, Phase 1, Phase 2, Completed, National Institute of Allergy and Infectious Diseases (NIAID)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications. Trials, record NCT05104723. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05104723
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
- NCT number
- NCT05104723
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Conditions
- Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease, Inflammatory Skin Disease, Inflammatory Lung Disease
- Interventions
- XELJANZ (tofacitinib)
- First posted
- 2021-11-03
- Last updated
- 2026-05-07
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of treatment-related toxicities. | Day 1 through Day 120 | To assess the safety of tofacitinib during the study period in patients with CGD. |
| Primary | Rate of infection. | Day 1 through Day 120 | To assess the safety of tofacitinib during the study period in patients with CGD. |
| Primary | Rate of AEs | Day 1 through Day 120 | To assess the safety of tofacitinib during the study period in patients with CGD. |
| Primary | Incidence of serious bacterial, mycobacterial, fungal, or viral infections defined as infections that require medical assessment or hospitalization. | Day 1 through Day 120 | To assess the safety of tofacitinib during the study period in patients with CGD. |
| Secondary | CGD-related IBD: 1.Change in modified HBI. 2.Change in histopathological endoscopy. | Day 90 | To assess the overall clinical response for the specific inflammatory manifestations. |
| Secondary | Skin disease: 1.Change in presence of skin flares or ulcerations by objective photography evaluation. | Day 90 | To assess the overall clinical response for the specific inflammatory manifestations. |
| Secondary | Inflammatory lung disease: 1. Change in FEV1. 2. Change in DLCO. 3.Change in CT radiography. 4. Change in 6-minute walk. | Day 90 | To assess the overall clinical response for the specific inflammatory manifestations. |
| Secondary | Gene expression: 1.Change in IFN gene module enrichment score derived from whole blood RNA expression data. | Day 90 | To assess the biological effect of tofacitinib on IFN-induced gene expression in CGD. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05104723
GET https://conductscience.org/api/trials/v1/NCT05104723/registered